A key driving force of the company is product extensions and Birkmayer USA is developing a number of products based on patented formulations/delivery systems of ENADA. With the introduction of a quick-acting form of NADH called Co-E1® NADH , Birkmayer USA launches a clinically proven countermeasure for jet lag.

In addition to product extensions, Birkmayer USA places a great emphasis and substantial investment in research collaboration and clinical trails at some of the world's leading medical institutions. Georgetown University Medical Center was the site of two Menuco ( former NY company of Prof. Birkmayer Health Products) studies of ENADA for Chronic Fatigue Syndrome and Alzheimer's disease. Results of the CFS study is published in the February 1999 issue of Annals of Allergy, Asthma & Immunology and the Alzheimer's study is projected for publication in a peer-reviewed medical journal by mid-2001. The studies follow rigorous FDA-approved testing procedures utilizing double-blind placebo controlled crossover human clinical studies considered as the "gold standard" by medical researchers. ENADAlert has also been the subject of medical clinical study. A double-blind placebo controlled study was conducted on subjects who took a "red eye" flight from San Diego, CA to Washington, DC (a flight spanning four time zones). ENADAlert proved to significantly relieve the effects of jet lag. The study results confirmed that ENADAlert helped reduce drowsiness and restored mental alertness. It also boosts stamina, endurance and energy without the use of stimulants. Further ENADAlert was found to have no side effects and is easy to take. Additionally, at the world renowned Sleep-Wake Disorders Center, Weill Cornell Behavioral Health at New York-Presbyterian Hospital is currently conducting a double-blind placebo controlled study to determine if ENADAlert will promote alertness and concentration in healthy individuals who are sleep deprived. Study results are expected by 1st Quarter, 2001.